Peripheral Arterial Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years, of any sex
• People who have been diagnosed with a build-up of fatty deposits (atherosclerosis) in the main or outer iliac arteries, which are located in the pelvis and upper leg area
• People whose leg symptoms fall within a specific range of severity, known as Rutherford classification 2 to 4, meaning symptoms ranging from mild pain during exercise to pain at rest (confirm with trial site)
• People, or their legal representatives, who are able to understand the purpose of the study, follow the study rules, and sign a consent form

Who may not be able to join:

• Women who are pregnant, planning to become pregnant, or currently breastfeeding
• People who have previously had a vascular graft (an artificial tube used to bypass or repair a blood vessel) placed in their iliac artery
• People who have had a stroke or heart attack within the 3 months before joining the trial
• People with known bleeding or clotting disorders that cannot be corrected, or with blood test results showing seriously abnormal clotting levels or a very low platelet count
• People whose kidney function is significantly reduced, based on a specific blood test result, or who are currently on dialysis
• People with blood test results showing significantly elevated liver enzyme levels (ALT or AST more than twice the normal upper limit)
• People with severe anaemia, meaning a very low red blood cell level (haemoglobin below 60.0 g/L)
• People with known allergies or intolerances to certain materials or medications used in the study, including cobalt-based alloys, a type of synthetic graft material (ePTFE), aspirin, clopidogrel, heparin, rivaroxaban, paclitaxel, contrast dye, or other study-related substances
• People who have had a vascular procedure within 30 days before the study surgery, or who plan to have one within 30 days after
• People who have received a clot-dissolving treatment in the target blood vessel within 14 days before joining the trial
• People with serious organ problems or other major health conditions that may affect their ability to follow the study rules, affect the results, or mean they are unlikely to complete the trial
• People currently participating in another clinical trial involving an experimental drug, biological treatment, or medical device
• People who the trial investigator considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.